Pozen Inc. v. Par Pharmaceutical, Inc.: “Fuzzy” limitations and the doctrine of equivalents.
- Published in:
- Journal of Generic Medicines, 2013, v. 10, n. 2, p. 139, doi. 10.1177/1741134313515666
- By:
- Publication type:
- Article
Works matching DE "PAR Pharmaceutical Cos. Inc."
Results: 8
1
2
Santarus, Inc. v. Par Pharmaceutical, Inc.: Is there a new written description requirement for negative limitations?
- Published in:
- Journal of Generic Medicines, 2013, v. 10, n. 1, p. 53, doi. 10.1177/1741134313481035
- By:
- Publication type:
- Article
3
MEGESTROL ACETATE APPROVED FOR WEIGHT LOSS IN AIDS.
- Published in:
- Journal of Pain & Palliative Care Pharmacotherapy, 2006, v. 20, n. 1, p. 92
- Publication type:
- Article
4
SURVEY OF RECENT DEVELOPMENTS IN INDIANA PRODUCT LIABILITY LAW.
- Published in:
- Indiana Law Review, 2014, v. 47, n. 4, p. 1129
- By:
- Publication type:
- Article
5
Companies, technology & environment.
- Published in:
- Chemistry & Industry, 2011, n. 18, p. 11
- By:
- Publication type:
- Article
6
Prohibition against off-label drug promotion challenged.
- Published in:
- Canadian Medical Association Journal (CMAJ), 2012, v. 184, n. 5, p. 518, doi. 10.1503/cmaj.109-4128
- By:
- Publication type:
- Article
7
Fidaxomicin.
- Published in:
- Drugs in R&D, 2010, v. 10, n. 1, p. 37
- Publication type:
- Article
8
Megestrol Acetate NCD Oral Suspension – Par Pharmaceutical: Megestrol Acetate NanoCrystal® Dispersion Oral Suspension, PAR 100.2, PAR-100.2.
- Published in:
- Drugs in R&D, 2007, v. 8, n. 4, p. 251, doi. 10.2165/00126839-200708040-00005
- Publication type:
- Article